Literature DB >> 34489160

LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‑induced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p.

Jian-Kai Tan1, Xiao-Feng Ma1, Guang-Neng Wang1, Chang-Rong Jiang1, Hui-Qin Gong1, Huan Liu2.   

Abstract

BACKGROUND: Coronary artery disease (CAD) is a common heart disease with high incidence and mortality. Myocardial ischemia is the main type of CAD, which negatively affects health worldwide. The aim of the present study was to investigate the function and mechanism of myocardial infarction-associated transcript (MIAT) in myocardial ischemia.
METHODS: Human cardiomyocytes (HCM) were treated with oxygen-glucose deprivation (OGD) to set the in vitro model and mouse myocardial ischemia/reperfusion (I/R) was set for in vivo model. Cell viability and apoptosis were detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay, flow cytometry, and immunofluorescence analysis. Inflammatory cytokines levels were detected by enzyme-linked immunosorbent assay. Gene and protein expressions were identified by quantitative real time-polymerase chain reaction or Western blotting. The interaction of MIAT, miR-181a-5p, and janus kinase 2 (JAK2) was identified by dual-luciferase report assay. Mouse heart tissues histopathological condition were observed by hematoxylin and eosin assays.
RESULTS: Expression of MIAT and JAK2 were increased in OGD-treated HCM and mice of I/R model group, and miR-181a-5p was decreased. MIAT silencing could reverse the OGD treatment induced cell proliferation inhibition, cleaved caspase-3 and Bcl2-associated X (Bax) levels increased, while those of B-cell lymphoma-2 (Bcl-2) and mitochondria's cyt-C decreased. Besides, MIAT knockdown attenuated the OGD-induced increase of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 levels. Moreover, MIAT targeted miR-181a-5p to enhance the expression of JAK2 and signal Transducer and Activator of Transcription 3 (STAT3), and miR-181a-5p overexpression promoted proliferation, whereas it inhibited apoptosis in OGD-induced cardiomyocytes. Furthermore, the regulatory effects of MIAT knockdown in cell proliferation, apoptosis, and inflammatory injury was reversed by inhibition of miR-181a-5p or overexpression of JAK2 in OGD-treated HCM. Knockdown of MIAT reduced myocardial injury caused by I/R treatment in vivo.
CONCLUSION: MIAT knockdown inhibited apoptosis and inflammation by regulating JAK2/STAT3 signaling pathway via targeting miR-181a-5p in myocardial ischemia model. MIAT can be a possible therapeutic target for controlling the progression of myocardial ischemia.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Coronary artery disease; JAK2; Long noncoding RNA; Mir-181a-5p; Myocardial infarction-associated transcript

Mesh:

Substances:

Year:  2021        PMID: 34489160     DOI: 10.1016/j.jjcc.2021.08.018

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

1.  Genipin protects against mitochondrial damage of the retinal pigment epithelium under hyperglycemia through the AKT pathway mediated by the miR-4429/JAK2 signaling axis.

Authors:  Wenshuang Xu; Qingyou Chen; Xiaofeng Zhang; Yue Zhao; Shuang Wu; Chao Yang; Yubao Liu; Lijie Liang; Di Jia; Chaojun Li; Li Fan; Yan Shi
Journal:  Ann Transl Med       Date:  2022-05

Review 2.  Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes.

Authors:  Jianxin Deng; Yunxiu Liao; Jianpin Liu; Wenjuan Liu; Dewen Yan
Journal:  Front Cell Dev Biol       Date:  2021-12-24

3.  Long non-coding RNA H19 contributes to spinal cord ischemia/reperfusion injury through increasing neuronal pyroptosis by miR-181a-5p/HMGB1 axis.

Authors:  Lili Guo; Dan Wang; Hildrich Yasmal Alexander; Xiaoyan Ren; Hong Ma
Journal:  Aging (Albany NY)       Date:  2022-07-05       Impact factor: 5.955

Review 4.  The crosstalk between STAT3 and microRNA in cardiac diseases and protection.

Authors:  Lan Wu; Zhizheng Li; Yanfei Li
Journal:  Front Cardiovasc Med       Date:  2022-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.